Neonatal adrenergic blockade following single dose maternal labetalol administration.
A single 30 mg intravenous dose of labetalol given 20 minutes prior to cesarean delivery at 35 weeks of gestation for severe pregnancy-induced hypertension was associated with symptoms of beta-adrenergic blockade (hypoglycemia, bradycardia, hypotension) in preterm twins. The infants were subsequently found to have therapeutic labetalol concentrations (180 and 150 ng/mL) in umbilical cord blood. The pharmacology of transplacental labetalol is reviewed and potential mechanisms for neonatal beta-adrenergic blockade are discussed.
Klarr
J M
JM
Department of Pediatrics, University of Michigan Medical Center, Ann Arbor.
Bhatt-Mehta
V
V
Donn
S M
SM
D000328:Adult; D001919:Bradycardia / Q000139:chemically induced*; D004200:Diseases in Twins; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007022:Hypotension / Q000139:chemically induced*; D007231:Infant, Newborn; D007741:Labetalol / Q000009:adverse effects* / Q000097:blood; D008297:Male; D008431:Maternal-Fetal Exchange / Q000502:physiology*; D011247:Pregnancy
D007741:Labetalol